Business, energy, technology, markets and global industry news from Business News Today

Phase 1b/2a clinical trial

PharmaDeviceNews Phase 1b/2a clinical trial
Sarepta enrolls non-ambulatory Duchenne patients in ELEVIDYS sirolimus safety study
Pharma & Biotech

Sarepta’s sirolimus gambit: Can enhanced immunosuppression rescue ELEVIDYS for non-ambulatory Duchenne patients?

Sarepta's ELEVIDYS Cohort 8 targets non-ambulatory Duchenne patients with a sirolimus regimen. What the trial design reveals about the path to label restoration.

Read More
Pharma & Biotech

Can Bioxytran’s ProLectin-M accelerate viral clearance in mild COVID-19?

Bioxytran reports early antiviral signal for ProLectin-M. Discover what this means for COVID-19 treatment strategy and regulatory risk.

Read More